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Letters to the Editorbetween off-pump and on-pump
CABG, which is contradictory com-
pared with Kuss and colleagues’
results from nonrandomized studies.
Late mortality in off-pump CABG is
another concern. In the meta-analysis
by Wijeysundera and coworkers,4
only 2 observational studies reporting
risk-adjusted effects on long-term
(1 year) outcomes showed essen-
tially no change in mortality (odds ratio
1.01; 95% CI, 0.74–1.40; P ¼ .93). In
the ROOBY trial,3 although no signif-
icant difference was found for the rate
of death from any cause within 1 year
(4.1% vs 2.9%; RR 1.41; 95% CI,
0.90–2.24; P ¼ .15), the rate of death
from cardiac causes within 1 year was
higher in the off-pump group than in
the on-pump group (2.7% vs 1.3%;
RR 2.05; 95% CI, 1.09–3.86; P ¼
.03). Our recent meta-analysis5 of 12
randomized trials (4326 patients en-
rolled) including the ROOBY trial
demonstrated a statistically significant
increase in late (1 year) all-cause
mortality by a factor of 1.37 with off-
pump relative to on-pump CABG
(RR 1.373; 95% CI, 1.043–1.808;
P ¼ .024).
Despite the superiority of off-pump
CABG to on-pump CABG in short-
term mortality found in Kuss and asso-
ciates’ meta-analysis1 of propensity
score analyses, on-pump rather than
off-pump CABG should be considered
at least for patients who meet the crite-
ria for enrollment in randomized trials
(typically for low- to moderate-risk
patients) because late, not short-term,
mortality reduction must imply the
greatest clinical benefit among patients
undergoing CABG.
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We thank Takagi and Umemoto1
for their interest in our recent system-
atic review of propensity score (PS)
analyses in off-pump versus on-pump
coronary artery bypass grafting.2 As
Takagi and Umemoto correctly point
out, our estimate for the effect of off-
pump coronary artery bypass grafting
on short-term mortality (odds ratio
[OR], 0.69; 95% confidence interval
[CI], 0.60–0.75) differs from the corre-
sponding estimate from randomized
controlled trials (RCTs). In their large
meta-analysis, Møller and colleagues3
found a relative risk of 0.98 (95% CI,
0.66–1.44). Takagi and Umemoto1
calculated a relative risk of 1.06
(95% CI, 0.67–1.67) by adding the re-
sults of the ROOBY trial4 to Møller
and colleagues’ results.
Setting aside the subtlety of equat-
ing ORs with relative risks, we would
like to point out 2 facts. First, even after
including the ROOBY results to the
data of Møller and colleagues,3 the CI
for the effect still includes our PS effect
estimate of 0.69. That means that even
data from nearly 100 randomized trials
on the off-pump/on-pump issue still
leave considerable uncertainty (as re-
flected by the large CI) on the size of
the true effect. In particular, ware still
far from achieving equivalent short-ardiovascular Surgery c August 2010term mortality, which Takagi and
Umemoto1 deduce from the current
data. This lack of information is also
emphasized by Møller and colleagues3
in their trial sequential analysis: The
authors state that demonstrating equiv-
alence or a minimal clinically relevant
effect of the off-pump technique on
mortality would require more than
240,000 patients.
Second, and this is also pointed out
correctly by Takagi and Umemoto,1
we do not expect the effect estimates
from PS analyses and RCTs to be
equal because the underlying study
populations usually differ. Patients in
RCTs are, in general, younger and
healthier than the average patient. In
a study currently under review, we re-
viewed 28 PS analyses and 51 RCTs
that compared off-pump and on-
pump coronary artery bypass graft-
ing.5 We found an average age of
65.8 years and an average left ventric-
ular ejection fraction of 58.8% in the
PS analyses, compared with an aver-
age age of 63.1 years and a mean left
ventricular ejection fraction of 62.7%
in the RCTs, confirming that patients
in the PS analyses are older and in
poorer health. After generating similar
study populations from PS analyses
and RCTs by a meta-matching algo-
rithm (resulting in a meta-matched
sample of 10 PS analyses and 29
RCTs), we found an OR for short-
term mortality of 0.53 (95% CI,
0.43–0.66) in the PS analyses and
0.58 (95% CI, 0.24–1.39) from the
RCTs, resulting in an OR difference
of0.05 (95% CI,0.56 to 0.47). Un-
fortunately, this difference is also as-
sociated with a large CI, but there is
some evidence (supported by other
clinical outcome data not shown) that
the treatments effects are similar, pro-
vided the underlying populations in
PS analyses and RCTs are similar.
Finally, we completely agree with
Takagi and Umemoto1 on the impor-
tance of long-term mortality. Sufficient
long-term mortality figures were avail-
able in 7 PS analyses in our data set,
initially accounting for 6813 patients.
Letters to the EditorBy restricting the analysis to informa-
tion provided only in the text (and
not, eg, extracted from Kaplan–Meier
curves) and considering only the effect
of the longest time of follow-up from
each study, we calculated an OR of
0.82 (95% CI, 0.67–1.02; P ¼ .07).
This shows that in PS analyses the
superiority of the off-pump approach
applies not only to short-term mortality
but also to long-term mortality, albeit
to a smaller degree.
Eventually, the results of current
randomized studies on risk groups
that mirror today’s typical patient pop-
ulations will elucidate the truth about
the differences between the on- and
off-pump approaches.
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Bad Oeynhausen, GermanyTABLE 1. Breakdown of extrapolated cost benefits of cryoprobe
Diagnostic yield with forceps biopsy at Glenfield Hospital, Leicester (%) 77%
Repeat bronchoscopy rate (%) 23%
No. of bronchoscopies with macroscopic tumor/year 132
No. of repeat bronchoscopies needed/year (132 3 23%) 30
Cost of standard bronchoscopy (2010 tariff) £504
Published improved relative increase in yield with cryobiopsy (%) 36%
Estimated diagnostic yield with cryobiopsy at Glenfield Hospital, Leicester (36%
relative increase on 77%) (%)
100%
Cost saving of cryobiopsy to Primary Care Trust (£504 3 30) £15,120
Cost of cryobiopsy equipment (cryosurgery unit and cable, adapter, probes, gas tube,
footswitch)
£7,500
No. of bronchoscopies to prevent to cover costs (7500/504) 15
Total annual costs (service contractþconsumables) £955
Residual cost savings after capital costs (15,120 – 7500) £7,620
Residual cost savings after annual costs (7620 – 955) £6,665
Residual cost savings, year 2 onward (15,120 – 955) £14,165References
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To the Editor:
I commend the study by Schumann
and colleagues1 that demonstrated the
clear superiority of cryobiopsy over
standard forceps biopsy for endolumi-
nal tumor, showing a 36% relative in-
crease and 24% absolute increase in
yield as the result of larger and less
fragmented samples.1 Unfortunately,
the acquisition of new equipment and
technology is hampered by resource
rationing in health care systems. Be-
cause tariff-base health care systems
require demonstration of cost benefit,
this article provides useful evidence
with which to develop cryobiopsy in
bronchoscopy units. At Glenfield
Hospital, Leicester, which includes
an annual number of 531 fiberoptic
bronchoscopies annually, we have
audited our own diagnostic yield with
forceps biopsy for endoluminal tumor
and found this to be only 77% overall
for 132 cases over 1 year with evi-
dence of tumor (with some variation
between trainees and consultants).2
By assuming a similar number of
bronchoscopies per year with endolu-
minal tumor with a similar yield with
forceps biopsy, this equates to 30 non-
diagnostic bronchoscopies (Table 1).
Under the National Tariffs for 2010
and 2011,3 the total extra annual cost
is calculated to be more than £15,000of Thoracic and Cardiovascular Surgeper year to the Primary Care Trust 9
(Table 1). By assuming a relative in-
crease in performance with cryobiopsy
similar to that reported by Schumann
and colleagues,1 this would translate
to a cost savings of more than
£15,000 per year (Table 1). The capital
cost of the cryobiopsy equipment
(£7500, ERBE Medical UK, personal
communication, May 2010) could be
covered by saving 15 repeat bronchos-
copies, which would take an estimated
6 months (at 30 saved per year; Table
1). After 1 year, residual cost savings
would total more than £6500 despite
deductions for capital, maintenance,
and consumable costs (Table 1). For
subsequent years, residual funds would
be in excess of £14,000 (Table 1).
The data provided by Schumann and
colleagues1 give respiratory physi-
cians the opportunity to provide a ro-
bust financial case for adding
cryobiopsy to their bronchoscopy unit
on the basis it will fund itself in 6
months, according to our own calcula-
tions and experiences. In addition, bet-
ter quality biopsies will provide better
material for bronchoscopic tissue re-
search studies and molecular markers.4
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